(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number
WO 01/45687 A3

(51) International Patent Classification[7]: A61K 31/506, A61P 25/24

(21) International Application Number: PCT/US00/34131

(22) International Filing Date:
18 December 2000 (18.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/172,684 20 December 1999 (20.12.1999) US
09/709,741 13 November 2000 (13.11.2000) US

(71) Applicant *(for all designated States except US)*: **FABRE-KRAMER PHARMACEUTICALS, INC.** [US/US]; Suite 3147, 5847 San Felipe, Houston, TX 77057 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KRAMER, Stephen, J.** [US/US]; 11300 Smithdale Road, Houston, TX 77024 (US). **FABRE, Louis, F.** [US/US]; 1310 Ridgely Drive, Houston, TX 77055 (US).

(74) Agent: **KELLY, Richard, D.**; Oblon, Spivak, McClelland, Maier & Neustadt, P.C., 4th Floor, 1755 Jefferson Davis Highway, Arlington, VA 22202 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
25 April 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/45687 A3

(54) Title: USE OF BIOACTIVE METABOLITES OF GEPIRONE FOR THE TREATMENT OF PSYCHOLOGICAL DISORDERS

(57) Abstract: Bioactive gepirone metabolites, such as 3-OH gepirone (4,4,-dimethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione), and their pharmaceutically acceptable salts and hydrates, can be used to alleviate psychological disorders or the symptoms thereof. The use of these compounds provides advantages over other therapeutic azapirones as they possess superior bioavailability, faster onset of action, and more stable plasma levels when administered to a mammal.